Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1004-1007

  Tsukada, Tomoharu ^a   Takahashi, Mizuki ^a   Takemoto, Toshiyasu ^a   Kanno, Osamu ^a   Yamane, Takahiro ^a   Kawamura, Sayako ^a   Nishi, Takahide ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Diabetes; FBPase

Indexed keywords

FRUCTOSE BISPHOSPHATASE; THIAZOLE DERIVATIVE; TRICYCLIC 8H INDENO[1,2-D][1,3]THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; HYDROGEN BOND; HYDROPHOBICITY; IC 50; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; METABOLISM; SYNTHESIS;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FRUCTOSE-BISPHOSPHATASE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 74049084628     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.056     Document Type: Article

References (19)

1. Benkovic S.J., and deMaine M.M. Adv. Enzymol. Relat. Areas Mol. Biol. 53 (1982) 45
2. Gidh-Jain M., Zhang Y., van Poelje P.D., Liang J.-Y., Huang S., Kim J., Elliott J.T., Erion M.D., Pilkis S.J., El-Maghrabi M.R., and Lipscomb W.N. J. Biol. Chem. 269 (1994) 27732
3. Zhang Y., Liang J., Huang S., and Lipscomb W.N. J. Mol. Biol. 244 (1994) 609
4. Iancu C.V., Mukund S., Fromm H.J., and Honzatko R.B. J. Biol. Chem. 280 (2005) 19737
5. Pilkis S.J., El-Maghrabi M.R., Pilkis J., and Claus T.H. J. Biol. Chem. 256 (1981) 3619
6. Wright S.W., Hageman D.L., McClure L.D., Carlo A.A., Treadway J.L., Mathiowetz A.M., Withka J.M., and Bauer P.H. Bioorg. Med. Chem. Lett. 11 (2001) 17
7. Wright S.W., Carlo A.A., Carty M.D., Danley D.E., Hageman D.L., Karam G.A., Levy C.B., Mansour M.N., Mathiowetz A.M., McClure L.D., Nestor N.B., McPherson R.K., Pandit J., Pustilnik L.R., Schulte G.K., Soeller W.C., Treadway J.L., Wang I.-K., and Bauer P.H. J. Med. Chem. 45 (2002) 3865
8. Wright S.W., Carlo A.A., Danley D.E., Hageman D.L., Karam G.A., Mansour M.N., McClure L.D., Pandit J., Schulte G.K., Treadway J.L., Wang I.-K., and Bauer P.H. Bioorg. Med. Chem. Lett. 13 (2003) 2055
9. Choe J.-Y., Nelson S.W., Arienti K.L., Axe F.U., Collins T.L., Jones T.K., Kimmich R.D.A., Newman M.J., Norvell K., Ripka W.C., Romano S.J., Short K.M., Slee D.H., Fromm H.J., and Honzatko R.B. J. Biol. Chem. 278 (2003) 51176
10. von Geldern T.W., Lai C., Gum R.J., Daly M., Sun C., Fry E.H., and Abad-Zapatero C. Bioorg. Med. Chem. Lett. 16 (2006) 1811
11. Lai C., Gum R.J., Daly M., Fry E.H., Hutchins C., Abad-Zapatero C., and von Geldern T.W. Bioorg. Med. Chem. Lett. 16 (2006) 1807
12. Hebeisen P., Kuhn B., Kohler P., Gubler M., Huber W., Kitas E., Schott B., Benz J., Joseph C., and Ruf A. Bioorg. Med. Chem. Lett. 18 (2008) 4708
13. Erion M.D., van Poelje P.D., Dang Q., Kasibhatla S.R., Potter S.C., Reddy M.R., Reddy K.R., Jiang T., and Lipscomb W.N. Proc. Natl. Acad. Sci. 102 (2005) 7970
14. Erion M.D., Dang Q., Reddy M.R., Kasibhatla S.R., Huang J., Lipscomb W.N., and van Poelje P.D. J. Am. Chem. Soc. 129 (2007) 15480
15. Dang Q., Rao Kasibhatla S., Reddy K.R., Jiang T., Reddy M.R., Potter S.C., Fujitaki J.M., van Poelje P.D., Huang J., Lipscomb W.N., and Erion M.D. J. Am. Chem. Soc. 129 (2007) 15491
16. van Poelje P.D., Dang Q., and Erion M.D. Drug Discovery Today 4 (2007) 103
17. Tsukada T., Takahashi M., Takemoto T., Kanno O., Yamane T., Kawamura S., and Nishi T. Bioorg. Med. Chem. Lett. 19 (2009) 5909
18. The X-ray crystallographic study was accomplished according to the procedure described in Ref. 8. The FBPase-6, 10b, 19a cocrystals were diffracted to 2.45, 2.8, 2.25 Å in resolution, respectively. The coordinates and statistics are available from the PDB using accession codes 3kbz, 3kc0, and 3kc1, respectively.
19. Inhibition assays using recombinant human liver FBPase were performed according to the methods described in Ref. 7c.